Although some studies suggest a potential risk of AKI with SGLT-2 inhibitors, a larger body of research, including studies involving patients with advanced diabetic nephropathy, has failed to demonstrate an increased risk of AKI. This evidence concerns the gene SLC5A2 and diabetic kidney disease.